A Phase 4 interventional study of Artesunate and Artesunate + Sulfadoxine-Pyrimethamine in Malaria, sponsored by Sanofi. Completed at 1 site in Mali. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2010-02-17.
Sponsored by Sanofi · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies testing artesunate in Malaria — none open to participants now, none under way, none of them phase 3. Artesunate · Malaria.
Among the 68 studies testing artesunate in Malaria, this one is the 14th largest by enrollment of the 66 interventional ones that give a count, is one of 6 that started in 2005, is one of 27 in phase 4, and was the 24th registered.
1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →None of the 68 studies testing artesunate in Malaria is open now. The open studies under Malaria, anywhere →
Artesunate: first FDA approval 2020 (ARTESUNATE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.
This study: 6 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 19 · Phase 4 27
First in 2000; this study’s year is marked. 6 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 780 is above the median of 252 across 938 interventional studies indexed under Malaria.
Median enrollment 290 across the 66 interventional studies. Of the 60 that completed or were terminated, 3 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 68 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
11 studies in Malaria by Sanofi: none open now, none under way, none of them phase 3. Of 11 finished, 0 (0%) have results posted.
Among the 11 studies in Malaria by Sanofi, this one is the 2nd largest by enrollment, is one of 2 that started in 2005, is one of 5 in phase 4, and was the 4th registered.
Sanofi’s Malaria studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 68 studies testing artesunate in Malaria, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 11 in Malaria:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Test the hypothesis that repeated administration of Artesunate/Amiodaquine, Artesunate/Sulfadoxine-Pyrimethamine and Arthemeter-Lufemantrine for the treatment of consecutive episodes of uncomplicated malaria reduces the incidence of uncomplicated falciparum malaria and malaria attributable anemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Arsucam® (AS 50mg/Aq153mg),oad, per os, 3 days of treatment
Drug: Artesunate
Arsumax (AS 50mg) + Sulfadoxine-Pyrimethamine (SP=SDX 500mg/PYR 25mg), oad, per os
Drug: Artesunate + Sulfadoxine-Pyrimethamine
Coartem (arthemether 20mg+ lumefantrine 120 mg), bid, per os. Duration of treatment: 3 days
Drug: arthemether + lumefantrine
oad, per os, 3 days of treatment
Drug page: Artesunate
oad, per os
bid, per os. Duration of treatment: 3 days
Clinical and parasitological cure rate
Time frame: at day 28
Clinical and biological tolerability
Time frame: During the study period
The record gives a start of Jul 2005, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Artesunate